Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -35,4x - -39,1x | -37,2x |
| Selected Fwd EBIT Multiple | 16,9x - 18,6x | 17,8x |
| Fair Value | €2,59 - €2,99 | €2,79 |
| Upside | -38,5% - -29,1% | -33,8% |
| Benchmarks | Ticker | Full Ticker |
| Amphastar Pharmaceuticals, Inc. | AMPH | NasdaqGS:AMPH |
| Corcept Therapeutics Incorporated | CORT | NasdaqCM:CORT |
| Teva Pharmaceutical Industries Limited | TEVJ.F | OTCPK:TEVJ.F |
| Recordati Industria Chimica e Farmaceutica S.p.A. | RCDT.F | OTCPK:RCDT.F |
| Novo Nordisk A/S | NONO.F | OTCPK:NONO.F |
| Xeris Biopharma Holdings, Inc. | 2B30 | DB:2B30 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| AMPH | CORT | TEVJ.F | RCDT.F | NONO.F | 2B30 | ||
| NasdaqGS:AMPH | NasdaqCM:CORT | OTCPK:TEVJ.F | OTCPK:RCDT.F | OTCPK:NONO.F | DB:2B30 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | 4.2% | 4.4% | 8.2% | 21.7% | NM- | |
| 3Y CAGR | 42.0% | 3.2% | 3.1% | 11.4% | 33.2% | NM- | |
| Latest Twelve Months | -8.0% | -9.9% | 2.4% | 10.1% | 31.6% | 63.6% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 19.3% | 28.5% | 18.9% | 30.7% | 44.0% | -232.7% | |
| Prior Fiscal Year | 31.0% | 22.2% | 20.1% | 30.1% | 45.1% | -26.8% | |
| Latest Fiscal Year | 28.1% | 20.3% | 20.4% | 29.8% | 48.2% | -13.6% | |
| Latest Twelve Months | 26.6% | 16.1% | 20.6% | 29.2% | 48.4% | -7.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.20x | 11.24x | 2.14x | 5.27x | 7.06x | 4.42x | |
| EV / LTM EBITDA | 6.5x | 69.2x | 8.0x | 14.7x | 13.8x | -226.9x | |
| EV / LTM EBIT | 8.3x | 69.8x | 10.4x | 18.0x | 14.6x | -60.0x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 8.3x | 14.6x | 69.8x | ||||
| Historical EV / LTM EBIT | -15.7x | -4.3x | -2.0x | ||||
| Selected EV / LTM EBIT | -35.4x | -37.2x | -39.1x | ||||
| (x) LTM EBIT | (16) | (16) | (16) | ||||
| (=) Implied Enterprise Value | 580 | 610 | 641 | ||||
| (-) Non-shareholder Claims * | (210) | (210) | (210) | ||||
| (=) Equity Value | 370 | 400 | 431 | ||||
| (/) Shares Outstanding | 160.2 | 160.2 | 160.2 | ||||
| Implied Value Range | 2.31 | 2.50 | 2.69 | ||||
| FX Rate: USD/EUR | 1.1 | 1.1 | 1.1 | Market Price | |||
| Implied Value Range (Trading Cur) | 2.04 | 2.21 | 2.38 | 4.21 | |||
| Upside / (Downside) | -51.4% | -47.4% | -43.4% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMPH | CORT | TEVJ.F | RCDT.F | NONO.F | 2B30 | |
| Enterprise Value | 1,613 | 7,581 | 41,635 | 12,121 | 2,164,351 | 971 | |
| (+) Cash & Short Term Investments | 237 | 323 | 1,697 | 333 | 41,550 | 58 | |
| (+) Investments & Other | 6 | 248 | 0 | 16 | 2,700 | 0 | |
| (-) Debt | (653) | (7) | (16,939) | (2,364) | (118,723) | (269) | |
| (-) Other Liabilities | 0 | 0 | (7) | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,203 | 8,145 | 26,386 | 10,106 | 2,089,878 | 761 | |
| (/) Shares Outstanding | 47.1 | 106.0 | 1,366.4 | 206.3 | 4,439.1 | 160.2 | |
| Implied Stock Price | 25.53 | 76.81 | 19.31 | 48.99 | 470.79 | 4.75 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 0.89 | 6.61 | 1.13 | |
| Implied Stock Price (Trading Cur) | 25.53 | 76.81 | 19.31 | 55.30 | 71.25 | 4.21 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 0.89 | 6.61 | 1.13 | |